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Background: Co-infection with malaria parasite and HIV is an emerging public health problem in tropical areas,
particularly in pregnant women, and management of the concurrent effects of these two infections is challenging.
Co-trimoxazole is a sulfamide preparation used to prevent opportunistic infections in HIV-infected patients, and
many studies have reported that it has significant activity against malaria. As the efficacy of intermittent preventive
treatment (IPT) with sulfadoxine-pyrimethamine (SP) against malaria is decreasing, co-trimoxazole might be an
alternative for preventing malaria among HIV-infected populations. The aim of this study is to compare the
effectiveness of SP-IPT, which is recommended for the prevention of malaria during pregnancy in the Central
African Republic, with that of a daily dose of co-trimoxazole against P. falciparum infections among HIV-infected
pregnant women in Bangui, the capital of the Central African Republic.
Methods/Design: The MACOMBA study (MAternity and COntrol of Malaria-HIV co-infection in BAngui) is a
multicentre open-label randomized clinical trial conducted at four maternity hospitals in Bangui. All HIV-infected
pregnant women presenting for an antenatal clinic visit between the weeks 16 and 28 of amenorrhoea, with a CD4
count of more than 350 cells/mm3, will be eligible. All the women will provide written consent before being
enrolled in the study and will then be randomly allocated to either SP-IPT (25 mg of sulfadoxine and 1.25 mg of
pyrimethamine) or daily co-trimoxazole doses (960 mg per dose). The primary end-point is the placental malaria
parasitaemia rate at delivery. Other main outcome measures include the number of malaria episodes during
pregnancy, safety, and treatment compliance. Furthermore, the frequency of molecular resistance markers dhfr and
dhps will be measured.
Discussion: In this trial, we seek to confirm whether co-trimoxazole is operationally suitable to replace SP-IPT in
order to prevent malaria among pregnant women infected with HIV in the Central African Republic.
Trial registration: ClinicalTrials.gov Identifier: NCT01746199
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Malaria and HIV infection are important global public
health problems. In 2008, malaria affected more than 2 bil-
lion people, representing 40% of the world’s population.
That same year, some 247 million episodes of malaria were
recorded, in addition to almost 1 million deaths, of which
nearly 20% were children. Each year, more than 50 million
women living in malaria-endemic regions become preg-
nant, 20% for the first time, and more than half develop
complications. In 2008, an estimated 33.4 million people
were living with HIV infection, and 2 million people, in-
cluding 280,000 children, died from AIDS-related diseases.
Sub-Saharan Africa is the most severely affected region: in
2007, it was estimated to contain 67% of all people living
with HIV in the world, 75% of all women infected with
HIV, and 72% of all deaths from AIDS [1]. These two en-
demic diseases are thus a double public health problem on
the African continent [2]. The interaction between HIV
infection and malaria was first described in 1992 [3],
and malaria is the third cause of death among people
infected with HIV, particularly pregnant women.
Effective integrated care of patients with malaria and
HIV infection in regions where the two coexist is there-
fore an international health challenge.
Relevance
Concurrent HIV infection and malaria during pregnancy
is an emerging problem in mother and child health, with
an estimated 1 million pregnancies per year among women
with both infection and malaria. In 11 of the 43 countries
of Africa in which malaria is endemic (Botswana, Burundi,
Central African Republic, Ethiopia, Malawi, Mozambique,
Rwanda, South Africa, Swaziland, Uganda and Zambia),
the prevalence of HIV infection among pregnant women
seen at antenatal visits varied from 10% to more than 25%
[4,5]. The estimated proportion of malaria cases due to
HIV-induced susceptibility during pregnancy is 4.8%
(95% confidence interval, 3.8 to 5.8), representing 50,382
additional cases of malaria [6].
As the clinical and biological symptoms of malaria are
enhanced by co-infection with HIV, pregnant women
with HIV infection more often have episodes of malaria
that evolve into complicated forms [7].
The World Health Organization (WHO) recommends
that pregnant women in endemic regions undergo four
antenatal examinations and receive two doses of sulfado
xine-pyrimethamine (SP) at each visit (directly observed
treatment (DOT)), beginning at week 16 of pregnancy [8].
Steketee et al. [9] however, reported a persistently high
rate of peripheral and placental parasitaemia after two
doses of intermittent preventive treatment (IPT) with sul
fadoxine-pyrimethamine (SP) in HIV-infected pregnant
women. Filler et al. [10] reported that a monthly dose
of SP was significantly more effective than two doses(prevalence of placental parasitaemia, 7.8% versus 21.5%
in HIV-positive women and 2.3% versus 6.3% in HIV-
negative women.
Ascertaining HIV serological status has become a pre-
requisite for better malaria prevention. The efficacy of
co-trimoxazole in preventing Plasmodium falciparum ma-
laria is well recognized. Thus, Mermin et al. [11] reported
a reduction of 40 malaria episodes per 100 person-years in
adults (other than pregnant women), and a clinical trial of
co-trimoxazole versus SP among children in Bandiagara,
Mali [12], showed a protective efficacy of 99.7%. Further-
more, several studies showed a good clinical and parasito-
logical response to co-trimoxazole in treated children
[13-16], and it has been reported to be safe in long-term
use during pregnancy [17].
Therefore, preventive treatment with SP for all HIV-
positive people (including pregnant women) who are re-
ceiving treatment containing co-trimoxazole is superfluous
and is even contraindicated in light of its common side-
effects (particularly severe skin reactions). Few studies,
however, have described the efficacy of co-trimoxazole in
preventing malaria among pregnant women, particularly in
areas where the frequency of therapeutic failures with SP
in cases of P. falciparum malaria is increasing.
The emergence of an increase in the frequency of resis-
tance of P. falciparum to SP in many sub-Saharan African
countries [18,19], including the Central African Republic
[20,21], challenges the short-term usefulness of this
drug combination in preventing malaria among preg-
nant women. The resistance is due to the accumulation of
point mutations at various sites on the genes that code for
dihydrofolatereductase (dhfr) and dihydropteroate syn-
thase (dhps). The number of mutations correlates with the
extent of P. falciparum resistance to SP in vitro. In studies
carried out in Bangui, the prevalence of therapeutic failure
was estimated to be 23.8% after 14 days of follow-up
among children with uncomplicated malaria [20], while
the resistance of P. falciparum to pyrimethamine in vitro
was reported to be 38.3% [21]. The frequency of triple mu-
tations in alleles Ile-51, Arg-59 and Asn-108 was 50.3%
[22], and there was a strong positive correlation between
the number of mutations and the resistance in vitro of
P. falciparum strains [23]. The triple mutations that can
occur in dhfr at Ile-51, Arg-59 and Asn-108 and the
double mutation at Gly-437 and Glu-540, alone or in com-
bination, are associated with therapeutic failure of SP [24].
Pregnancy and HIV infection increase the risk for
emergence of mutated strains that are resistant to SP,
partly because a wide variety of types and clones are
found in parasitaemia among pregnant women (genetic
diversity) [25], but also because the circulating biomass
of P. falciparum has increased due to the HIV epidemic
[26]. There is still concern about the possible develop-
ment of cross-resistance of P. falciparum to both co-
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action, although this hypothesis has not been proven
[27,28]. A study of the response of wild parasites mutated
in the dhfr and dhps genes to SP and co-trimoxazole
in vitro showed partial cross-resistance to the two drugs
[29]. Mutations in Arg-59 of dhfr and Gly-43 of dhps corre-
lated with P. falciparum resistance to co-trimoxazole [15].
The current prevalence of malaria among women at
first presentation to an antenatal clinic in Bangui is esti-
mated to be 23% [30]. Since 2006, the national malaria
programme has established administration of SP-IPT, with
two doses for HIV-negative women and three doses for
those who are HIV-positive [31].
In 2011, we assessed data from maternity centres of
Bangui and found that more than 75% of pregnant women
accepted HIV testing. This finding is in accordance with
the recommended threshold of acceptance [32]. Our pre-
liminary evaluation showed a relatively high rate of HIV
infection (7.3%) among pregnant women. The profile of
HIV serological status and rates of prevention of mother-
to-child transmission (MTCT) are detailed in Table 1.
To prevent opportunistic infections, co-trimoxazole is
given to all women at WHO clinical stages 2, 3 and 4
and those at stage 1 with a CD4+ count <350/mm3 from
the second trimester and throughout pregnancy [33].
In the Central African Republic, two treatment schemes
are recommended for the management of HIV infections
during pregnancy [32]:
 Antiretroviral treatment is offered to all pregnant
women with severe or clinically advanced disease,
regardless of their CD4+ count, and for those with a
count of ≤350 cells/mm3, regardless of their
symptoms. Treatment begins at any time during
pregnancy. First-intention treatment should
comprise zidovudine (AZT) plus lamivudine (3TC),
with nevirapine (NVP) or efavirenz (EFV). Breastfed
infants should receive NVP or AZT throughout
breastfeeding.
 Women who are ineligible for antiretroviral
treatment are given a preventive regime to reduce
HIV MTCT: (i) AZT from week 16 of amenorrhoea,
(ii) AZT, 3TC and NVP during labour and delivery
and (iii) AZT and 3TC for 7 days after delivery.
Breastfed infants receive a dose of NVP at birth and







Castors 612 461 (75.3) 34 (7
Communautaire 1218 887 (72.8) 70 (7
Amitié 716 602 (84.1) 38 (6Infants who are not breastfed are given a single dose
of NVP at birth, followed by one dose per day of
NVP or AZT up to the age of 6 weeks.Hypothesis
Our main hypothesis is that co-trimoxazole is more effica-
cious than SP-IPT against placental parasitaemia, perhaps
due to a higher plasma concentration of co-trimoxazole
attained with daily doses. If we validate this hypothesis, co-
trimoxazole could be recommended as prophylaxis for
HIV-positive pregnant women, regardless of their CD4+
cell count. In this study, we will also test the hypothesis
that the strains of P. falciparum isolated from HIV-positive
pregnant women express more dhfr and dhps resistance
markers.Methods/Design
Aims
The main objective of this randomized trial is to con-
firm that co-trimoxazole is more efficacious than SP
against placental parasitaemia (primary end-point) among
HIV-positive pregnant women with a CD4+ count >350
cells/mm3.
We will also compare the two treatments with regard
to adherence, the occurrence of adverse events, the fre-
quency of maternal anaemia (hemoglobinaemia <10 g/dl),
malaria episodes during pregnancy, abortions, stillbirths,
prematurity (birth <37 weeks of amenorrhoea) and low
birth weight (<2500 g), placental malaria, umbilical mal-
aria transmission, and mother-to-child HIV transmission.Study design
The MACOMBA study (MAternity and COntrol of
Malaria-HIV co-infection in BAngui) is a multicentre
randomized controlled open-label trial to compare SP-IPT
with co-trimoxazole. The study will be open-label, because
it will be impossible to blind the pregnant women and
health-care workers involved to which group the women
are assigned. Furthermore, we seek to compare the two
strategies under real-life conditions.
The trial will be performed by the Institut Pasteur
of Bangui, supported by Institut Pasteur of Paris. The
four main maternity hospitals in Bangui are involved





Number receiving prevention of
mother-to-child transmission
.4) 28 (82.3) 23 (82.1)
.9) 57 (81.4) 55 (96.5)
.5) 36 (92.3) 30 (83.3)
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HIV-seropositive pregnant women will be recruited in
the four maternity clinics. All pregnant women attending
maternity clinics will be offered an HIV test as part of
the standard procedure of HIV counselling [34]. Inclu-
sion in the study will be offered to all women presenting
for their first visit between weeks 16 and 28 of amenor-
rhoea and with confirmed HIV infection. Women who
arrive for their first antenatal visit before week 16 of
pregnancy can be included at their second visit if they
are eligible. Women who already know their HIV status can
also be included if their CD4+ count is >350 cells/mm3 and
they have no opportunistic diseases (WHO stage 2, 3 or 4).
These women will not be re-tested for HIV, but their CD4+
count will be checked at this stage of inclusion in the study.Eligibility criteria
The inclusion criteria are age ≥18 years, HIV positivity;
gestation of 16 to 28 weeks; CD4+ count >350 cells/mm3
and no sign of WHO stage 2, 3 or 4, agreement to attend
all antenatal consultations for the study, willingness to ad-
here to all the requirements of the study (including volun-
tary counselling and testing for HIV) and signed informed
consent.
The exclusion criteria are psychological instability that
might interfere with compliance, hypersensitivity to sul-
famides or dermatological disease (eczema, pemphigoid ex-
anthema) that would increase the risk for severe reaction
to the drugs being tested; severe anaemia (Hb <7 g/dl),
known hepatic cardiac or renal disease, or any other severe
disease.Recruitment and randomization
Potential study participants will be identified by midwives
at antenatal clinics. Women eligible for participation in
the study will be invited for additional counselling by a re-
search midwife to ensure that they are fully informed or-
ally and by written material about the nature of the study.
After providing informed consent to participate in the
study, the women will be randomly allocated to either the
SP-IPT or co-trimoxazole group.
Randomization of women will be centralized and strati-
fied according to maternity clinic and gravidity (primigrav-
idae versus multigravidae). For each maternity clinic, two
random lists for SP-IPT and co-trimoxazole in a ratio 1:1
will be generated for primigravidae and multigravidae, with
the R software (version 2.14.1). Once a pregnant woman is
confirmed to be eligible for the study, the field investigator
will telephone the coordination staff at the Institut Pasteur
of Bangui to indicate the gravid rank, and the site staff
will assign women to a treatment arm according to the
randomization list, respecting the chronological order of
inclusion.Intervention
Study drugs
The drugs to be used in this study will be supplied
by the International Dispensary Association in the
Netherlands. Doses of SP-IPT and co-trimoxazole will
be administered from week 16 to the end of pregnancy.
Three doses of SP will be administered under direct
observation, equivalent to 25 mg of sulfadoxine and
1.25 mg of pyrimethamine per kilogram of body
weight. The first dose will be given between weeks 16
and 28 of amenorrhoea, the second 1 month later and
the third 1 month after the second.
A daily dose of one co-trimoxazole tablet (containing
160 mg trimethoprim and 800 mg sulfamethoxazole) will
be given until delivery [17]. Compliance will be evalu-
ated at each antenatal visit, by questioning the women
about the doses they have taken and by asking them to
bring to the visit all remaining tablets.
All women will be given iron supplementation (200 mg)
and folic acid (0.4 mg) and will receive an insecticide-
impregnated bed net (donated by the Total Group in
Central African Republic and the National Malaria
Programme).
During follow-up, any suspected malaria episode will
be followed up immediately with parasitological evalu-
ation (blood smear). Treatment with quinine at a dose
of 24 mg/kg body weight will be given at three doses
per day 8 hourly apart for 7 days. The tablet form of
quinine will be given in the absence of severe clinical
signs. If the malaria episode is associated with severe
clinical symptoms, quinine (perfusion in 10% serum
glucose) will be administered parenterally at a dose of
24 mg/kg body weight per day until clinical evaluation
shows that oral quinine can be taken. Patients who
experience adverse effects of quinine will be treated
with artemether or artemisinin combined treatment ac-
cording to national guidelines.
A woman who fulfils all the inclusion criteria but is
found to have symptomatic malaria parasites at recruit-
ment will be treated for the malaria episode and will not
be included in the study. She will be reconsidered for in-
clusion later, when she is no longer parasitaemic. All
women with asymptomatic malaria parasites at baseline
will be included and randomized to either the SP-IPT or
co-trimoxazole group. If symptomatic malaria or persis-
tence of asymptomatic malaria parasitaemia is seen 8
days later, the woman will be given curative treatment,
as stated above (Figure 1).
Management of adverse events during follow-up
All women included in this study will undergo regular
clinical surveillance (once a month) and will be encour-
aged to notify the doctor involved in the study of any ad-
verse events. The adverse effects attributed to SP-IPT
Figure 1 MACOMBA trial flowchart. 3TC: lamivudine; ACTs: artemisinin combined therapies; AZT: zidovudine; CTM: co-trimoxazole; DBS: dried
blood spot; DBSd: dried blood spot for early diagnosis of HIV mother-to-child transmission; DOT: direct observed treatment; MTCTc: mother-to-child
transmission of HIV and malaria parasite; NVP: nevirapine; PCRa, polymerase chain reaction for Plasmodium resistance markers; PCRb, nested
species-specific polymerase chain reaction; RDT: rapid diagnostic test; SP: sulfadoxine-pyrimethamine; V1 to V5: follow-up visits; VL: viral load.
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neous toxicity, classified according to the grades of the
French National Agency for AIDS Research. Symptomatic
medications will be given, and the study may be inter-
rupted at the discretion of the clinicians.
All adverse events associated with HIV infection or anti-
retroviral treatment will be managed by the national ser-
vice for prevention of MTCT.
All women whose HIV infection evolves to clinical stage
2 or who have a CD4 count interval of ≤350 per mm3 will
be sent to the centre for antiretroviral treatment at the
Hôpital Communautaire or Hôpital de l’Amitié with a re-
ferral to the service for infectious diseases.Data collected
At baseline, the following data will be collected: socio-
demographic characteristics, clinical data, obstetric his-
tory, gestational age estimated from the date of the last
menstrual period and/or measured by uterine fundal
height, and biological end-points (CD4 count, HIV viral
load (VL), malaria diagnosis, and blood cell count). Dur-
ing follow-up, standard clinical examinations will be
performed monthly. Adverse events will be recorded and
any suspected malaria episode will be investigated by
laboratory testing. Blood will be taken from women pre-
senting with a malaria episode, and CD4 count and HIV
VL will be determined.
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and identification of resistant strain markers (dhfr and
dhps) will be performed for all episodes of Plasmodium
infection.
At delivery, the women’s blood will be analysed for
CD4 count, HIV VL, blood cell count, and malaria diag-
nosis (thick smear analysis and rapid diagnostic test for
malaria and nested species-specific PCR). At this point,
MTCT of HIV and possible passage of the malaria para-
sites though umbilical blood circulation will be assessed.
Blood drawing
Venous blood will be collected in ethylenediaminetetra-
acetic acid (EDTA) minicollect tubes at inclusion, at
scheduled and unscheduled antenatal clinic visits if a
malaria infection is diagnosed, and after delivery. These
blood samples will be tested for blood cell counts and
HIV VL estimation. Finger pricks for thick and thin blood
smear preparation and antigen Pf/Pan-SD Bioline™ rapid
diagnostic testing will be performed for any suspected epi-
sodes of malaria during follow-up. Maternal blood will be
also collected on filter paper for Plasmodium DNA extrac-
tion. Early screening of HIV and malaria parasites trans-
mission in infants will be determined from heel-prick and
umbilical blood respectively. Placental blood will be col-
lected immediately after delivery. For this procedure, a
block of tissue (1 × 1 × 1 cm) will be excised from the
basal side of the placenta, resulting in a large pool of
intervillous blood at the excision site. The placental tissues
will be pressed to prepare thin and thick blood smears
(Figure 1).
Laboratory analysis
Malaria rapid diagnostic tests and thick smear analyses
will be performed at the study sites, while other labora-
tory analyses will be performed at the Institut Pasteur of
Bangui.
CD4+ cells will be counted by cytometry (FACSCalibur™,
Becton Dickinson, San Jose, CA, USA), and blood cell
counts will be conducted by the ABX PENTRA 60
(HORIBA ABX Diagnostics, Irvine, CA, USA).
HIV VL will be estimated at the Institut Pasteur of
Bangui with the ABI PRISM 7000 (Generic HIV kit; Bio-
centric, Bandol, France).
Generic HIV DNA Cell kits (Biocentric, Bandol, France)
will be used for PCR to assess maternal-child transmission
of HIV infection.
The antigen Pf/Pan-SD Bioline™ rapid diagnostic test
will be conducted according to the manufacturer’s guide-
lines. Thick blood smears will be air-dried, stained with
4% Giemsa and analysed under a light microscope (× 100
oil immersions) to detect asexual forms of P. falciparum.
Nested species-specific PCR will be performed to screen
maternal and placental blood samples for malaria parasitesas described previously [35]. The greater sensitivity of
PCR than of rapid diagnostic tests and microscopy has
been proven [36,37].
Molecular studies to identify Plasmodium resistance
markers to pyrimethamine and sulfadoxine (dhfr and dhps)
will be performed on blood samples with a positive malaria
result. The genotypes pfdhfr 51, 59 and 108 and pfdhps 437
and 540 will be determined by nested PCR [38].
Outcome measures
The primary end-point of the trial is placental parasit-
aemia at delivery. Data on this variable will be coded as
positive or negative results. Other outcome measures are
adherence to co-trimoxazole treatment, adverse events
related to co-trimoxazole and SP-IPT, the incidence of
malaria episodes during pregnancy and complications due
to malaria: anaemia (hemoglobinaemia <10g/dl), abortion
(delivery <28 weeks of amenorrhoea), stillbirth, prematur-
ity (birth <37 weeks of amenorrhoea) and low birth weight
(<2500 g body mass), mother-to-child HIV transmission
and umbilical blood parasitaemia. At delivery, maternal,
placental and newborn umbilical blood will be sampled to
detect the asexual form of Plasmodium.
Statistical considerations
Sample size
On the basis of previous studies [10,17,39,40], we antici-
pate that there will be 6.2% placental malaria infections
in the co-trimoxazole group and 16.8% in the SP-IPT
group. We will therefore randomize 300 women (type I
error of 0.05, power of 80%, one-sided test), of whom
150 will be in the experimental group and 150 in the
control group.
Statistical analysis
The primary end-point will be analysed as intention-to-
treat; deaths and women lost to follow-up will be con-
sidered failures. Analysis of the ‘per protocol’ population
will be conducted among women who complete the
study until delivery and undergo the recommended ini-
tial treatment.
The data will be recorded in an ACCESS™ database
(Microsoft Corp., Redmond, WA, USA) and will be ana-
lysed with STATA™ software (version 12; Statacorp, Col-
lege Station, TX, USA). The analyses will be carried out
after stratification according to the maternity clinic and
gravidity (primigravidae versus multigravidae). The chi-
squared test or Fisher’s exact test will be used to compare
categorical variables between the two groups, including
the number of positive placental malaria infections (pri-
mary end-point), cumulated incidence of malaria episodes
during pregnancy, proportion of parasite strains with dhfr
mutations, maternal anaemia and maternal morbidity or
mortality. Student’s t test or the Mann-Whitney test will
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A logistic regression model will be used, with adjustment
for maternity clinic, gravidity, age, CD4 count and anaemia
to compare the two groups of women for the number of
placental malaria infections, malaria episodes during preg-
nancy, and identified resistance.Ethical and legal considerations
The National Ethics Committee of the Central African
Republic and the Clinical Research Committee of the
Institut Pasteur in Paris approved the study protocol.Discussion
In this trial, we seek to confirm that co-trimoxazole is
operationally suitable to replace SP-IPT in order to pre-
vent malaria among pregnant women infected with HIV
in the Central African Republic. Studies of alternatives
to SP in preventing malaria during pregnancy have been
designed in Benin [41,42]. The MACOMBA project will
provide further information about the suitability of co-
trimoxazole for malaria prevention among HIV-infected
pregnant women, regardless of their CD4 count. It may
result in better management and therefore better out-
comes for infected pregnant women. The women in-
cluded in this study will receive adapted therapeutic care
and regular, standardized biological follow-up, which will
improve their quality of life and ensure satisfactory preg-
nancies. At the community level, the project will sensitize
the population, offering them a better understanding of
the risks associated with malaria, both for pregnant
women and for the infants. It should also strengthen pre-
vention of MTCT of HIV, which remains relatively high
(11%) in the Central African Republic (Ministry of Public
Health, Population and AIDS Control, unpublished data).
If the frequency of mutations in malaria parasites is found
to be higher in the SP arm of this study, all seropositive
women will be offered treatment with co-trimoxazole.
The results of this study will be communicated to health
policy-makers and experts who make recommendations
about malaria prevention among HIV-positive women.Trial status
This study is currently being implemented.
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